Aviceda Therapeutics is a technology company.
Aviceda Therapeutics has raised $210.0M across 1 funding round.
Key people at Aviceda Therapeutics.
Aviceda Therapeutics has raised $210.0M in total across 1 funding round.
Aviceda Therapeutics is a clinical-stage biotechnology company developing glyco-immune therapeutics that target innate immune dysfunction to treat inflammatory diseases, particularly in ophthalmology such as geographic atrophy (GA) and diabetic macular edema (DME).[1][2][3][4] Its lead product, AVD-104, is a dual-targeted therapy delivered via biodegradable nanoparticles that inhibits complement factor H (CFH) and macrophages, aiming to improve best corrected visual acuity (BCVA)—a key unmet need in GA treatments.[2][3] The company serves patients with ocular, fibrotic, oncologic, and neurologic conditions through a pipeline including AVD-302 for diabetic retinopathy, AVD-401 for retinoblastoma, and preclinical programs like AVD-601 for lung cancer and AVD-801 for neurogenic inflammation, leveraging its proprietary Glyco-Code® platform and cell-based high-throughput screening for precise immunomodulation.[1][3][4]
Founded in 2018 and based in Cambridge, MA, Aviceda has raised under $10M in funding and is backed by investors like Catalio Capital, with recent leadership appointments signaling growth momentum toward late clinical stages.[2][3][6]
Aviceda Therapeutics was founded in 2018 by Dr. Mohamed Genead, an experienced ophthalmologist serving as Co-Founder, CEO, and President, alongside Dr. Michael Tolentino, Co-Founder and CTO—both practicing ophthalmologists passionate about retina conditions.[2][3][5][6] The idea emerged from recognizing the glycome's vast diversity in regulating innate immune checkpoints, far exceeding the proteome or genome, to address chronic non-resolving inflammation in diseases like dry age-related macular degeneration (AMD).[3][4] Early traction built on their Glyco-Code® technology, enabling engineered glyco-ligands for immune cell modulation, with pivotal moments including partnerships like Catalio Capital and recent executive hires: Dr. Jeffrey Nau as CEO in April 2025 (ex-TYRVAYA launcher) and Dr. Emmett T. Cunningham, Jr. to the board (serial biotech founder).[2][5][6]
Aviceda rides the glyco-immune modulation trend, exploiting the glycome's untapped potential to reprogram innate immunity—key to chronic inflammation in aging populations and diseases like AMD, where complement inhibitors fall short.[1][3][4][7] Timing aligns with booming ophthalmology biotech, fueled by GA/DME market growth (e.g., post-IZERVAY success) and nanoparticle advances for targeted delivery.[2][5] Favorable forces include rising unmet needs in non-resolving inflammation across fibrosis and neurodegeneration, plus investor interest in precision immunomodulators amid 2025's top biopharma deals.[6] Aviceda influences the ecosystem by pioneering GCTs, potentially expanding "checkpoint" paradigms beyond oncology to innate immunity, enabling cross-disease platforms.[4]
Aviceda is poised for clinical readouts on AVD-104 in GA/DME, with Phase 2/3 momentum driving partnerships or acquisition—echoing leaders' past $5.9B exits.[2][5][6] Trends like glyco-engineering and dual-immune targeting will accelerate its pipeline into fibrosis and oncology trials by 2026, unlocking multi-billion markets if BCVA data validates superiority.[1][2] Its influence may evolve from niche ophtho player to broad innate immune leader, harnessing nature's design for transformative therapies in an inflammation-dominated disease landscape.[7]
Aviceda Therapeutics has raised $210.0M in total across 1 funding round.
Aviceda Therapeutics's investors include Omega Funds, SV Health Investors.
Key people at Aviceda Therapeutics.
Aviceda Therapeutics has raised $210.0M across 1 funding round. Most recently, it raised $210.0M Series C in January 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2025 | $210.0M Series C | Omega Funds, SV Health Investors |
